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It is becoming increasingly evident that steady-state mRNA levels do not always reflect the 
cellular proteome composition. Pathways that regulate mRNA translation determine the 
repertoire of proteins being expressed. Deregulation of processes involved in translation 
control participate in the development and progression of different diseases including cancer 1. 
Tumoral cells modulate translational programming to increase the activity of components of 
the translation machinery. This boosts the overall protein synthesis capacity and favors the 
expression of specific oncogenic networks. Hence, therapeutic strategies that target 
components of the translation machinery to decrease protein synthesis rates and rewire 
translation programs hold promise in a broad range of cancer types 1. Various compounds have 
been shown to affect protein synthesis and are investigated as possible cancer therapeutics. 
Among these, we recently described that the HIV aspartyl protease inhibitors (HIV-PIs), a 
family of antiviral drugs, regulate pathways that modulate mRNA translation 2.  
The HIV-PIs were designed to specifically target the HIV protease. These safe and orally 
available molecules have been successfully used for more than two decades to decrease viral 
loads in infected patients. Intriguingly, early studies indicated that patients treated with these 
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drugs had a significant reduction in HIV-associated tumors 3. Further studies have 
demonstrated that Nelfinavir (NFR), one of the first HIV-PIs to be approved by the FDA, 
showed promising anticancer properties in mice and in non-infected cancer patients. This led 
to phase I and phase II clinical trials that were designed to evaluate NFR repositioning in 
various cancer types 3. Nevertheless, the mechanisms underlying NFR and HIV-PIs anti-
tumoral properties remained poorly understood 3. 
In a previous study we showed that NFR targets translation program by inducing the integrated 
stress response (ISR) 4. This response is driven by the phosphorylation of the translation 
initiation factor eIF2α to decrease overall translation initiation and increase production of 
stress factors including the transcription factor ATF4. While the ISR is a key response that 
modulates cellular homeostasis, this pathway did not affect cellular viability in presence of the 
HIV-PIs. In contrast, we found that NFR-mediated toxicity relied on the activation of the 
kinase eEF2K 2 (Figure 1).  
The eukaryotic elongation Factor 2 Kinase (eEF2K), belongs to a small group of proteins 
containing an α-kinase catalytic domain 5. It mainly functions as a negative modulator of 
protein synthesis through its ability to phosphorylate and inhibit its unique known target: the 
translation elongation factor eEF2. This factor mediates GTP-dependent tRNA-mRNA duplex 
translocation through the ribosome. Therefore its inhibition negatively impacts protein 
synthesis. The eEF2K pathway restores cellular homeostasis upon conditions of nutrient or 
energy depletion by decreasing translation rates at the stage of elongation. Within tumors, 
decreased protein synthesis by eEF2K activation has been proposed to contribute to tumor 
adaptation under nutrient depletion and stress conditions including hypoxia 6.  
In contrast to its possible oncogenic role, increased activation of eEF2K by treatment with 
rapamycin (an inhibitor of mTORC1), has been shown to dampen tumor growth in a model of 
colorectal cancer 7. In line with these findings we found that NFR and other HIV-PIs elicited a 
sustained eEF2K activation that decreased protein synthesis, impaired cell proliferation and 
promoted cell-death. Moreover, eEF2K deficiency within tumors impaired NFR-mediated 
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anticancer activity in immunocompromised mice, indicating that pharmacological eEF2K 
activation drives a tumor intrinsic response that impairs tumor growth 2.  
The molecular mechanisms by which NFR triggers eEF2K activation are still unidentified. 
Main known pathways involved in eEF2K activation, including those downstream of 
rapamycin, were found to be dispensable, suggesting that NFR mode of action defines a new 
mechanism of eEF2K activation. In addition, NFR did not promote the expected increase of 
the polysomal fraction, but led to the accumulation of free ribosomes in an eEF2K dependent 
manner, indicating that eEF2K activation may affect other steps of the translation process 
beyond its role in regulating elongation. This possibility may reveal a new facet of eEF2K 
function and therefore needs to be addressed in details. 
Another important question is to understand how eEF2K activation dampens tumor growth. 
One hypothesis is that tumor cells are particularly sensitive to the general decrease in mRNA 
translation. Because the expression of eEF2K and its activity have been reported to be 
increased in many tumors 6, it is possible that pharmacological eEF2K activation and 
subsequent decrease of mRNA translation, may exceed the bearable threshold of overall 
decrease in protein synthesis. Therefore, in stressed tissues, eEF2K activation originally aimed 
at reducing the energy consuming processes of mRNA translation, may exacerbate the toxicity 
of eEF2K activating compound such as NFR. It is also possible that, rather than its function in 
reducing global protein translation, eEF2K drives specific alteration of the repertoire of 
translated genes that may directly impact tumor growth. Whether eEF2K activation 
preferentially affects factors involved in survival and proliferation remains to be addressed. A 
global approach analyzing how eEF2K activation rewires the translational landscape may 
provide hints on how the pharmacological activation of this stress kinase affects oncogenic 
processes. 
No doubt that these questions will spark a renewed interest in the therapeutic benefits of 
targeting translation programs in cancer.  
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Figure legend:  
Translational control by Nelfinavir. Nelfinavir inhibits translation initiation by triggering the 
phosphorylation of eIF2α. Moreover, Nelfinavir promotes the activation of the kinase eEF2K 
leading to the phosphorylation of the elongation factor eEF2, thereby blocking its ability to 
promote translation elongation. In addition eEF2K activation may affect a yet to be defined 
step in the initiation process. EEF2K activation by Nelfinavir dampens tumor growth.  
 
